Compare Cytokinetics Inc (CYTK) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs GSK plc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 10.7× Cytokinetics Inc's market cap, and GSK plc pays a 3.9% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and GSK plc for 93 Days on average.
| CYTK | GSK | |
|---|---|---|
Market Cap | $8.62B | $91.88B |
Volume | 2,594,626 | 7,730,529 |
Sector | Health | Health |
52-Week High | $87.26 | $61.18 |
52-Week Low | $54.76 | $43.24 |
Typical Hold Time | 19 Days | 93 Days |
Enterprise Value | $8.72B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% today, amid bearish technical signals but strong analyst optimism. The stock shows negative profitability with a -1,321.12% net income margin and P/S ratio of 114, reflecting high growth expectations. Recent Phase 3 trial successes for aficamten in hypertrophic cardiomyopathy position the company for potential FDA approval and commercial expansion, driving the 97% buy rating consensus with a $112.60 price target.
The outlook balances clinical progress against financial strain. While aficamten's recent data and commercial launch of MYQORZO offer significant upside, persistent cash burn and high valuation multiples present substantial risk. Investors face binary outcomes dependent on regulatory success and market penetration versus ongoing operational losses.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
